Melius reiterates Buy on Mirion Technologies stock on nuclear base By Investing.com

Mirion reported Q4 EPS $0.15 versus $0.16 expected and revenue $277.4M versus $278.85M, narrowly missing estimates; the stock showed resilience in pre-market trading. Melius reiterated a Buy with a $29 price target (shares at $19.29, market cap $4.62B), highlighting 47% of revenue tied to nuclear, LTM revenue $925M, 47% gross margin, revenue growth forecast of 23% in FY2026, a 30% adjusted EBITDA target driven by operating leverage, procurement consolidation contributing +100bps near-term (150–300bps through 2028), and $39M in SMR bookings in 2025 (+$10M in January); PEG is 0.97 but InvestingPro flags the stock as overvalued vs Fair Value.

Analysis

Mirion sits at the intersection of a structural services re‑rating and a volatile near‑term execution cycle; the long‑run thesis is durability of recurring, high‑margin service revenue but the path there requires reliable backlog conversion and margin realization. Procurement consolidation across utilities will compress vendor count and concentrate negotiating leverage — that should lift stable share for incumbents with certification and calibration networks, but it will also create periodic pricing pressure where utility procurement teams extract one‑time concessions before normalizing. Small modular reactors (SMRs) amplify content delivered per MW during construction, which front‑loads revenue and working capital needs for instrumentation vendors; this creates a two‑stage cashflow profile (early capex recognition, later recurring aftermarket annuity) that conventional multiples underappreciate. The main operational risk is execution: missed integration of digitized service offerings or slower life‑extension contracts will delay operating‑leverage benefits and leave the stock sensitive to sequential quarterly misses rather than the multi‑year secular case.

Key Decisions for Investors

• Initiate a tactical long in MIR (size 2–4% net exposure) with a 12–18 month horizon to capture re‑rating as recurring revenues scale; protect with a 20–25% stop and plan to take 50% of position off at +50% and remainder at +100% to crystallize operating‑leverage optionality while limiting single‑quarter execution risk.
• Pair trade: Long MIR (2.5% weight) / Short BWXT (BWXT) (1.5% weight) for 9–12 months to isolate services/aftermarket re‑rating versus new‑build/fuel exposure; target relative outperformance of 20–30% and cut if the pair moves against you by 10% (protects vs macro swings in nuclear capex).
• Options structure to express convexity: buy Jan‑2027 MIR LEAP calls sized for 1% portfolio delta exposure and sell nearer‑term calls (3–6 month) to fund 40–60% of the premium — outright loss limited to premium, upside asymmetry >2.5x if multi‑year secular adoption accelerates.
• Event hedge / short trigger: if the next quarter shows sequential backlog conversion miss or management pulls margin guidance, initiate a tactical short or buy puts (6–9 month) sized to 50% of the long exposure to hedge execution risk; unwind on clear reacceleration of bookings or guidance reinstatement.